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Abstract
Background: To evaluate the safety of focal dose escalation to regions with standardized uptake value (SUV) >2.0
using intensity-modulated radiation therapy (IMRT) by comparison of radiotherapy plans using dose-volume
histograms (DVHs) and normal tissue complication probability (NTCP) for postoperative local recurrent rectal cancer
Methods: First, we performed conventional radiotherapy with 40 Gy/20 fr. (CRT 40 Gy) for 12 patients with
postoperative local recurrent rectal cancer, and then we performed FDG-PET/CT radiotherapy planning for those
patients. We defined the regions with SUV > 2.0 as biological target volume (BTV) and made three boost plans for
each patient: 1) CRT boost plan, 2) IMRT without dose-painting boost plan, and 3) IMRT with dose-painting boost
plan. The total boost dose was 20 Gy. In IMRT with dose-painting boost plan, we increased the dose for BTV+5
mm by 30% of the prescribed dose. We added CRT boost plan to CRT 40 Gy (summed plan 1), IMRT without dose-
painting boost plan to CRT 40 Gy (summed plan 2) and IMRT with dose-painting boost plan to CRT 40 Gy (summed
plan 3), and we compared those plans using DVHs and NTCP.
Results: Dmean of PTV-PET and that of PTV-CT were 26.5 Gy and 21.3 Gy, respectively. V50 of small bowel PRV in
summed plan 1 was significantly higher than those in other plans ((summed plan 1 vs. summed plan 2 vs. summed
plan 3: 47.11 ± 45.33 cm
3 vs. 40.63 ± 39.13 cm
3 vs. 41.25 ± 39.96 cm
3(p < 0.01, respectively)). There were no
significant differences in V30,V 40,V 60,D mean or NTCP of small bowel PRV.
Conclusions: FDG-PET-guided IMRT can facilitate focal dose-escalation to regions with SUV above 2.0 for
postoperative local recurrent rectal cancer.
Background
Although positron emission tomography using
18F-fluor-
odeoxyglucose (FDG-PET) has become widely used for
diagnosis of various malignant tumors, the spatial reso-
lution of PET images alone is not high and it is difficult
to determine anatomical sites in detail. However, this
problem has been solved by the use of a combined
PET/CT system, which enables both PET and CT
images to be obtained at almost the same time and at
the same position.
Local recurrence rates of rectal cancer after surgery
including dissection of lateral nodes have been reported
to be about 9~12% in Japan [1-3], and the prognosis
after local recurrence is poor. In the case of local recur-
rence, the best salvage treatment for achieving long--
term local control and survival is total pelvic
exenteration with distal sacrectomy. The 5-year overall
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reported to be 30~40% [4,5]. Since about half of the
patients with local recurrent rectal cancer die due to
only local lesions without distant metastasis [6], local
control would be beneficial for survival. However,
extended surgery is not widely used because of high
morbidity and mortality rates. Moreover, it has been
pointed out that total pelvic exenteration reduces the
quality of life of patients. Furthermore, Tepper et al.
reported that only 34% of patients with locally or dis-
tantly recurrent rectal cancer could receive a potentially
curative resection [7]. In Japan, due to the lower rate of
local recurrence after surgery alone, induction radiother-
apy is not performed in most patients [8]. And, based
on SEER, over 30% of patients with advanced-stage rec-
tal cancer in the United States also did not undergo
radiation therapy [9]. Therefore, external body radio-
therapy is one of the most widely used therapies and
provides good palliation of pain in 50~80% of patients
with postoperative local recurrence; however, it has a
poor survival benefit [10]. We have been performing
conventional irradiation for postoperative local recurrent
lesions with a total dose of 60 Gy (2 Gy/fraction · 5 frac-
tions/week), but we have considered that dose escalation
is necessary to cure patients because rectal cancer has
many hypoxic fractions [11]. In fact, some studies have
revealed that local failure rate after radiotherapy alone
decreased with increasing irradiation dose [12,13]. How-
ever, dose escalation with conventional radiotherapy is
difficult due to the location of critical organs (e.g, small
bowel) around the lesion.
Huebner et al. showed by a meta-analysis that the sen-
sitivity, specificity and accuracy of FDG-PET for local
recurrent rectal cancer were 94.5%, 97.7% and 95.9%,
respectively [14]. FDG-PET is superior to conventional
modalities (e.g, CT and MRI) for distinguishing between
local recurrence and postoperative scar. There have
been several reports recently on the usefulness of FDG-
PET for radiotherapy planning in lung cancer and head
and neck cancer. FDG-PET has been reported to be use-
ful for delineation of target gross tumor volume (GTV)
or clinical target volume (CTV).
We performed FDG-PET/CT planning in 12 patients
with postoperative local recurrent rectal cancer during
conventional radiotherapy at 40 Gy.
As a preclinical study, we planned focal dose escala-
tion to high FDG uptake regions in those 12 patients
with intensity-modulated radiation therapy (IMRT) in
the radiotherapy planning system, and we compared the
IMRT plans with conventional radiotherapy plans in
dose-volume histograms (DVHs) and normal tissue
complication probability (NTCP).
The purpose of the present study is to evaluate the
safety of focal dose escalation to regions with
standardized uptake value (SUV) above 2.0 using IMRT
in DVH and NTCP in patients with postoperative locor-
egional recurrent rectal cancer
Methods
Criteria for eligibility
Eligibility criteria were as follows: (1) postoperative
locoregional recurrent rectal cancer, (2) unresectable, (3)
age between 20 and 79 years, (4) Karnofsky Performance
Status (KPS) score of > = 60, (4) without distant metas-
tasis, (5) tumor is grossly measurable, and (6) no serious
medical or psychologic conditions precluding safe
administration of treatment.
Radiotherapy
A linear accelerator (Clinac 23EX (VARIAN Medical
Systems, Palo Alto, CA), 6 or 15 MV) was used as the
X-ray source.
First, we performed radiotherapy planning using CT
with contrast medium for 12 patients with postoperative
locoregional recurrent rectal cancer. All target volumes
were outlined slice by slice on the treatment-planning
CT images. GTV was defined as the gross extent of the
tumor shown by imaging as well as physical examina-
tion, CTV was defined as GTV plus a 10-mm circular
margin for potential microscopic spread, and planning
target volume (PTV) was defined as CTV plus a 5-mm
circular margin to account for organ motion and patient
setup errors. Additionally, we attached a 5-mm leaf mar-
gin to PTV. The patients were prescribed 40 Gy in 20
fractions with the dose prescribed to the isocenter (CRT
40 Gy) using a median of 4 (range 3-4) coplanar irradia-
tion fields.
Next, we performed FDG-PET/CT with a carbon gra-
phite flat tabletop in the supine position for radiotherapy
planning at 40 Gy in the same 12 patients. The images
obtained by CT and PET were sent to the radiation ther-
apy planning system as DICOM data, and the CT and
PET images were fused using DICOM information. Resi-
dual gross extent of the tumor shown in CT images at 40
Gy was defined as GTV2, CTV-CT was defined as GTV2
plus a 5-mm circular margin, and PTV-CT was defined
as CTV-CT plus a 5-mm circular margin. We defined the
regions with standardized uptake value (SUV) above 2.0
as biological target volume (BTV) and BTV+5-mm circu-
lar margin as PTV-PET. Our radiotherapy planning sys-
tem could show the degree of FDG accumulation with
not SUV but Bq/ml in PET images. If the total dose of
FDG administered to the patient and the patient’sb o d y
weight are known, we can define regions with an arbi-
trary range of SUVs even in our radiotherapy planning
system by adjusting the window level and range. In the
present study, we delineated BTV under the condition
showing SUV of 2.0 to 20.0.
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tional radiotherapy plan (CRT boost plan), 2) IMRT plan
not using dose painting (IMRT without dose-painting
boost plan), and 3) IMRT plan using dose painting
(IMRT with dose-painting boost plan) (Figure 1). The
fractional dose of radiotherapy was 2.0 Gy with normali-
zation at 95% of PTV-CT, and the total boost dose was
20.0 Gy. In IMRT dose-painting boost plan, we increased
the dose of PTV-PET by 30% of the prescribed dose (2.6
Gy/fraction, total 26.0 Gy) using dose-painting.
We defined the small bowel as the organ at risk
(OAR) because the small bowel is the most vulnerable
to radiation in pelvic organs, and we carefully delineated
the whole small bowel in the abdomen and pelvis, pre-
ferably with the colon, bladder or other organs with
reference to CT using contrast medium. The planning
organ at risk volume (PRV) was margined with 5 mm to
the OAR as with the PTV margin.
IMRT plans were generated using Varian Eclipse
(Helios IMRT) Workstations. The beam arrangement
consisted of seven coplanar non-colinear fields (30°, 80°,
130°, 180°, 230°, 280°, 330°), and delivery of IMRT was
carried out using the sliding window technique with a
15 MV linear accelerator equipped with a dynamic mul-
tileaf collimator. Our primary inverse planning objec-
tives were as follows: (1) uniform dose of 20 Gy to
PTV-CT (relative weight, w = 15), (2) maximal irra-
diated dose (Dmax) of small bowel PRV <20 Gy (w =
20) (total Dmax of small bowel PRV <60 Gy), (3) dose
received by 5% (D5) of small bowel PRV <15 Gy (w = 8)
(total D5 of small bowel PRV <55 Gy), and in the IMRT
with dose-painting boost plan, we added (4) dose
received by 95% (D95) of PTV-PET >26 Gy (w = 10)
(total D95 of PTV-PET >66 Gy, which means
normalized 2-Gy-equivalent biologically effective dose,
67.3 Gy, calculated using an alpha/beta value of 10).
IMRT planning for this study was theoretical and was
not used for treatment. All of the patients underwent
conformal radiation therapy to a total dose of 60~66 Gy
(2.0 Gy/fraction/day).
We added each boost plan to CRT 40 Gy (summed
plan 1: CRT 40 Gy + CRT boost plan, summed plan 2:
CRT 40 Gy + IMRT without dose-painting boost plan,
summed plan 3: CRT 40 Gy + IMRT with dose-painting
boost plan) (Figure 2) and we compared those plans
using DVHs and NTCP of small bowel PRV.
The differences in dose distribution between IMRT
without dose-painting boost plan and IMRT with dose-
painting boost plan were evaluated by the conformity
index (C.I.), which we defined as the ratio of the volume
irradiated with 95% of the prescribed dose to PTV-CT.
NTCP
NTCP was calculated using the Lyman-Kutcher-Burman
model.
NTCP 
  12 2
2 / exp( / ) ,   dx
t
(1)
t (D- TD m TD  50 50 ( )) /( ( )).  (2)
Irradiation of fractional volume v =V / V ref corre-
sponds to parameter TD50 (v) for 50% complication
probability, given by the following power law:
TD  TD
n
50 50 () .  
 (3)
Figure 1 Pattern diagram of the present planning study.
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With inhomogeneous irradiation, there are multiple
partial volume irradiations to different doses. The effects
of partial volume irradiations are computed according to
the Kutcher-Burman (K-B) effective-volume dose-
volume histogram reduction scheme [15]. The K-B
method satisfies the consistency requirement that parti-
tioning a uniform irradiation of the entire volume into
multiple partial volume irradiations to the same dose
results in the same NTCP. The organ dose is described
as independent fractional volume elements vj,( j = 1,...
k),  j
j
k
 
1
= 1, irradiated to doses dj. Then, with the K-B
algorithm, an effective fractional volume Veff(j) defined
as follows is computed for each vj. The effective frac-
tional volume is the volume that, when irradiated to
reference dose dref, would give the same complication
probability in the Lyman model as the actual fractional
volume vj irradiated to dose dj.I fvj were the only frac-
tional volume irradiated, then from equality of effect
and Eq. (B), it would follow that
Vd / d eff(j) j
1/n  jr e f () . (4)
In the K-B method, Eq. (D) is applied to all fractional
subvolumes. In the present study, dref was chosen to be
the maximum dose Dmax. The total effective fractional
volume receiving the reference dose is calculated as fol-
lows:
VV eff j
j
k
eff 
  () ,
1
(5)
using v =V eff in Eq. (C) and D = dref =D max in Eq. (B)
The parameters used to calculate small bowel obstruc-
tion and perforation were n =0 . 1 5 ,m = 0.16, and TD50
= 55 [16,17].
Chemotherapy
For all of the 12 patients, S-1 60 mg/m
2 was given orally
twice daily (within 30 minutes after morning and eve-
ning meals) for 2 weeks, followed by a drug-free interval
of one week (one cycle) concomitant with radiation
therapy. Chemotherapy was not performed for a period
of at least 4 weeks before initiation of radiation therapy
in any of the patients.
FDG-PET
PET scans were performed 1 hour after administration of
18F-fluorodeoxyglucose at a dose of 3.1 MBq/kg using a
Biograph PET/CT scanner (Siemens, Hoffman Estates,
IL) under the condition of more than 4 hours of fasting.
A transmission scan was performed for attenuation cor-
rection before the emission scans (using a computed
tomography scan). Seven bed positions were used for
emission scans, with an acquisition time of 2 minutes per
position. For radiotherapy planning, PET/CT scans were
performed in the same posture as that for treatment on a
flat carbon-fiber table top. The PET images were recon-
structed with an ordered-subset expectation maximiza-
tion (OSEM) iterative reconstruction algorithm.
For semiquantitative analysis of increased FDG uptake
lesions, SUV based on body weight (g) was calculated
and converted into a value based on lean body mass:
SUV [tissue activity concentration (Bq/ml)]/[administered   a activity (Bq)/weight (g)].
The blood glucose levels of all patients before scans
were less than 150 mg/dl.
Statistical analysis
Statistical significance was defined as a value of p < 0.05
in the present study. SPSS software for Windows version
11.0 (SPSS Inc, Chicago, IL) was used for all calcula-
tions. Multiple pairwise comparisons were performed by
Figure 2 Dose distribution of s u m m e dp l a n3(summed plan of CRT 40Gy and IMRT with dose-painting boost plan) in a patient.a ) :
dose distribution in CT, b): dose distribution in FDG-PET.
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ferroni method.
Ethics
The present study protocol was reviewed and approved
by the Ethics Committee of Tohoku University Graduate
School of Medicine (approval number, 2007-418), and
informed consent was obtained from all patients before
radiation therapy.
Results
The results of comparison of the plans in all 12 patients
are shown in Additional file 1; Table S1. Even with the
fusion method using DICOM information, there were
no significant displacements between PET images and
CT images. We did not need to fuse them manually
again. The locations of the highest level of FDG accu-
mulation after 40 Gy in local recurrent regions were
almost the same as those before radiation therapy in the
12 patients, but maximal SUV decreased significantly
from 6.84 ± 3.25 before radiation therapy to 5.14 ± 2.81
at 40 Gy (p = 0.035, Wilcoxon’st e s t ) .F i g u r e3s h o w s
change in FDG accumulation caused by irradiation of 40
Gy in a patient with anastomotic recurrence. In the pre-
sent study, although there was no significant difference
between GTV and GTV2 (GTV vs. GTV2: 87.52 ±
63.06 cm
3 vs. 79.66 ± 57.80 cm
3, p = 0.141), there was a
significant difference between GTV2 and BTV (GTV2
vs. BTV: 79.66 ± 57.80 cm
3 vs. 11.12 ± 21.92 cm
3,p<
0.001) (Additional file 1; Table S2). In the IMRT with
dose-painting boost plan, mean irradiated dose (Dmean)
of PTV-PET and that of PTV-CT were 26.5 ± 0.8 Gy
and 21.3 ± 0.8 Gy, respectively.
With regard to the volume of small bowel PRV receiv-
ing 50 Gy or more (V50), there were significant differ-
ences between s u m m e dp l a n1and summed plan 2 and
between s u m m e dp l a n1and s u m m e dp l a n3(summed
plan 1 vs. s u m m e dp l a n2vs. summed plan 3: 47.11 ±
45.33 cm
3 vs. 40.63 ± 39.13 cm
3 vs. 41.25 ± 39.96 cm
3
(p < 0.01, respectively)) (Additional file 1; Table S2).
With regard to the volume of small bowel PRV receiv-
ing 60 Gy or more (V60), 40 Gy or more (V40), 30 Gy or
more (V30)a n dD mean of small bowel PRV, there were
no significant differences (summed plan 1 vs. summed
plan 2 vs. summed plan 3:V 60, 19.76 ± 23.67 cm
3 vs.
13.65 ± 18.88 cm
3 vs. 14.52 ± 19.18 cm
3;V 40, 77.32 ±
64.21 cm
3 vs. 71.33 ± 60.20 cm
3 vs. 72.55 ± 61.59 cm
3;
V30, 121.18 ± 119.6 cm
3 vs. 113.62 ± 99.69 cm
3 vs.
116.88 ± 104.94 cm
3;D mean, 16.1 ± 5.8 Gy vs. 16.4 ± 5.6
Gy vs. 16.6 ± 5.8 Gy (n.s.)) (Figure 4 and 5, Additional
file 1; Table S2).
Focal dose escalation using dose-painting slightly but
significantly increased maximal irradiated dose (Dmax)o f
small bowel PRV(summed plan 1 vs. summed plan 2 vs.
s u m m e dp l a n3 : 55.0 ± 16.0 Gy vs. 54.9 ± 15.3 Gy vs.
57.4 ± 16.3 Gy (p < 0.01, respectively)); however NTCP
of small bowel PRV was not significantly increased even
using focal dose escalation (summed plan 1 vs. summed
plan 2 vs. summed plan 3: 5.10 ± 5.66% vs. 3.78 ±
4.19% vs. 4.09 ± 4.62%) (Additional file 1; Table S2). In
the 4 patients with lateral pelvic lymph node metastasis
or perineum recurrence, there were no significant
Figure 3 Change in FDG accumulation. This patient had anastomatic recurrence with 7.3 SUVmax before radiation therapy. After 40 Gy, the
accumulation was decreased by 3.1 SUVmax.
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(summed plan 1 vs. summed plan 2 vs. summed plan 3:
Dmax, 41.5 ± 23.9 Gy vs. 42.5 ± 23.4 Gy vs. 43.8 ± 24.2
Gy; NTCP, 4.45 ± 8.84% vs. 2.95 ± 5.87% vs. 3.30 ±
6.57%). In 8 patients with presacral or anastomostic
recurrence, Dmax of small bowel PRV of summed plan 3
was significantly higher than that of summed plan 2 (p
= 0.006) but was not significantly higher than that of
summed plan 1 (n.s.) (summed plan 1 vs. summed plan
2 vs. summed plan 3: 61.8 ± 0.6 Gy vs. 61.1 ± 1.1 Gy vs.
64.2 ± 3.0 Gy); however, IMRT could significantly
decrease NTCP of small bowel PRV. There was no sig-
nificant difference in NTCP of small bowel PRV
between s u m m e dp l a n2and summed plan 3 (summed
plan 1 vs. summed plan 2 vs. s u m m e dp l a n3 :5.42 ±
4.05% vs. 4.19 ± 3.56% vs. 4.49 ± 3.82%, p < 0.005,
respectively). The mean DVH of small bowel PRV of
summed plan 3 in patients with lateral pelvic lymph
node metastasis or perineum recurrence and that in
patients with presacral or anastomostic recurrence are
shown in Figure 6.
In the present study, although Dmax of small bowel
PRV of s u m m e dp l a n3was slightly higher than that of
summed plan 1 or s u m m e dp l a n2 ,V 50 of small bowel
PRV could be reduced by IMRT, and V30,V 40,V 60,
Dmean and NTCP were not increased even using focal
dose escalation.
There was also no significant difference in C.I.
between IMRT without dose-painting and IMRT with
dose-painting (IMRT without dose-painting boost plan
vs. IMRT with dose-painting boost plan: 1.33 ± 0.10 vs.
1.29 ± 0.61 (p = 0.115)).
Discussion
To our knowledge, there are few reports on PET-guided
IMRT for lower gastrointestinal cancer. The reasons
w h yw eu s e dt h i sp l a n n i n gm e t h o df o rp a t i e n t sw i t h
local recurrent rectal cancer were 1) FDG-PET enabled
a recurrent tumor to be distinguished from postopera-
tive scar, 2) FDG-PET could reveal the region with
higher malignancy activity and 3) it was not necessary
to consider large inter- and intra-fractional motions
because of adhesion due to the operation.
There have been several reports on PET/CT radio-
therapy planning in lung cancer and in head and neck
carcinoma. This planning method has been reported to
be useful for radiotherapy to delineate target volume.
With regard to FDG, there is evidence that FDG-avid
regions of a tumor show increased radioresistance in
vitro [18,19] and hypoxia in vivo [20]. Therefore, FDG-
PET/CT is also useful for radiotherapy planning to
detect the region with high residual potency in GTV to
be given priority for treatment with a high dose.
It is difficult to clearly show threshold accumulation
between malignancy and non-malignancy by FDG-PET
because there is usually inflammation around a malig-
nant tumor, there is penumbra of high accumulation
and the normal gut tube has slightly high uptake of
Figure 4 Mean DVH (whole curve) of small bowel PRV in each summed plan.
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get volume according to 40~50% of maximal SUV value,
source-background ratio, and arbitrary SUV value in
some malignant tumors [21-25]; however, it remains
inconclusive. Bayne et al. pointed out that SUV value
had problems with accuracy and reproducibility [26]. In
the present study, although we used an arbitrary SUV of
2.0, we consider that it is not a clear border between
malignancy and non-malignancy but a region with rela-
tively high malignant potency and with resistance to
radiation at 40 Gy including a subclinical margin like
CTV margin. Although SUV of 2.5~3.0 was used as a
threshold value between malignancy and non-malig-
n a n c yi nm a n yp r e v i o u ss t u d i e s ,w eu s e dS U Vo f2 . 0a s
Figure 5 Mean DVH (focused on high dose area (50 to 70 Gy)) of small bowel PRV in each summed plan.
Figure 6 Mean DVH of small bowel PRV of summed plan 3 in patients with lateral pelvic lymph node metastasis or perineum
recurrence and that in patients with presacral or anastomostic recurrence. In patients with lateral pelvic lymph node metastasis or
perineum recurrence, the mean DVH of small bowel PRV of summed plan 3 was significantly lower than that in patients with presacral or
anastomostic recurrence.
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patients in the present study had already been irradiated
with 40 Gy and based on the fact that Haberkorn et al.
reported the mean SUV of recurrent rectal cancer after
radiotherapy with 40 Gy to be 1.8 [27].
Furthermore, in the present study, since normal tis-
sues around the GTV were also irradiated with 40 Gy,
the possibility that radiation-induced inflammation
masked a residual malignant tumor must also be consid-
ered. For other tumors such as head and neck cancer
and lymphoma [28,29], chemoradiation-induced inflam-
matory response causes sufficient numbers of false-posi-
tive results limiting PET being performed less than 2
months after chemoradiation. It may be inappropriate to
use FDG-PET for radiation planning during radiation
therapy. Recently, chemotherapy consisting of 5-FU or
Capecitabine with or without the addition of Oxaliplati-
num has commonly been performed for recurrent rectal
cancer. Also, in the present study, all patients under-
went concomitant and/or previous chemotherapy with
radiation therapy. Findlay et al. mentioned the so-called
flare phenomenon that occurs at 1~2 weeks after the
initiation of chemotherapy and that can be observed as
am a r k e di n c r e a s ei nF D Gm e t a b o l i s mi nl e s i o n st h a t
show response later [30]. We may also have to investi-
gate the appropriate thresholds of FDG accumulation
for BTV for each type of chemotherapy. However, in
rectal cancer, many investigators revealed that the posi-
tive predictive value of FDG-PET assessment of therapy
response during or soon after chemoradiation was very
high and was not significantly limited by post-chemora-
diation changes [31]. The timing of FDG-PET after che-
moradiation for the most accurate assessment of tumor
response in rectal cancer is controversial. Further larger
prospective surveys of the time courses of tumor FDG
uptake during and after chemoradiation in rectal cancer
are required.
There are other major problems regarding the use of
PET/CT for radiation therapy planning: misalignment of
the fusion of PET and CT images due to body move-
ment, bowel peristalsis and difference in volume of
urine between the transmission scan and emission scan
as well as artifacts due to FDG in urine, so-called “hot
urine”. These problems can be resolved to a large extent
by overnight fasting before PET/CT and by starting the
emission scan from the position of the pelvis. Moreover,
in the present study, a 5-mm circular margin was
attached to each target volume and OAR; however, it
might not be sufficient to cover such misalignment. It is
necessary to investigate such misalignment using on-line
imaging (e.g., cone-beam CT) before clinical application.
In the present study, since V30,V 40,V 60,D mean and
NTCP of small bowel PRV were not increased and V50
of small bowel PRV could be reduced due to the
differences between GTV2 and BTV, focal dose escala-
tion by 6 Gy to regions with SUV above 2.0 using
IMRT with dose-painting boost for postoperative local
recurrent rectal cancer is considered to be safe. FDG-
PET-guided IMRT has the possibility of improving local
control of postoperative local recurrent rectal cancer
without increasing the risk of radiation injury of small
bowel PRV. However, although NTCP which reflects
account all the DVH data was not increased, Dmax of
small bowel PRV in the summed plan using focal dose
escalation was significantly higher than that in other
summed plans. While the differences in mean Dmax of
small bowel PRV between summed plan 3 and the other
plans were only about 2.5 Gy in the present study, Dmax
of small bowel PRV in s u m m e dp l a n3was more than
65.0 Gy in 4 of the 8 patients with anastomotic or pre-
sacral recurrence, and NTCP in s u m m e dp l a n3in 2 of
the 4 patients was more than 10%. Since it is known
that the small bowel is a “serial organ” and that the
dose at which probability of obstruction or perforation
is 50% within 5 years after treatment (TD50/5) of the
small bowel is 55 Gy [32], although NTCP shows that
focal dose escalation is acceptable, dose escalation by
only 6 Gy from 60 Gy even using PET-guided IMRT is
relatively risky. Therefore, if the region of high FDG
accumulation is near the OARs, it might be necessary to
r e d u c et h ed e g r e eo fd o s ee s c a l a t i o na n d / o rr e d u c et h e
volume to increase irradiation dose (e.g., lesion with
SUV > 2.5). Alternatively, using IMRT from the begin-
ning of radiotherapy, using a belly board, and inserting
a spacer between the recurrent tumor and OARs may
further facilitate dose escalation without increasing the
risk of radiation injury. When PTV-PET overlaps PRV,
we may have to further modify the irradiation dose set-
ting of the overlapping part.
Rectal cancer is known to have many hypoxic frac-
tions [11]. Some studies have provided evidence that
hypoxia has a negative impact on tumor response to
radiation and other methods of therapy [33-36].
Although we used FDG for radiotherapy planning in
this study to determine the region with high tumor
cell density, it may be more important for improving
the effect of radiotherapy for rectal cancer to deter-
mine the hypoxic regions. There are some tracers for
detecting a hypoxic region (e.g., [
18F]Fluoromisonida-
zole-3-fluoro-1-(2’-nitro-1’-imidazolyl)-2-propanol
([
18F]FMISO), Cu-diacetyl-bis(N4-methylthiosemicar-
bazone (Cu-ATSM) and 1-(2-fluoro-1-[hydroxymethyl]
ethoxy)methyl-2-nitroimidazole ([
18F]FRP170)) [37-39].
Although Lin et al. have already reported the effective-
ness in head and neck cancer [40], increasing the irra-
diation dose with IMRT to the hypoxic region may
also be effective for treating postoperative recurrent
rectal cancer.
Jingu et al. BMC Cancer 2010, 10:127
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Our findings suggest that FDG-PET/CT-guided IMRT
can facilitate focal dose escalation to regions with SUV
above 2.0 while providing normal tissue protection in
patients with postoperative local recurrent rectal cancer.
However, we do not recommend routine clinical use of
focal dose escalation using FDG-PET/CT-guided IMRT.
In cases in which the region of high FDG accumulation
is near the OARs, careful radiotherapy planning is
necessary. Based on the results of this planning study,
we will start a clinical phase I/II study of focal dose
escalation using PET-guided IMRT for patients with
postoperative local recurrent rectal cancer in our
institution.
Additional file 1: Supplementary tables.
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